NAVAMEDIC (NAVA.OL) Stock Fundamental Analysis
Europe - OSL:NAVA - NO0010205966 - Common Stock
21.4 NOK
-0.1 (-0.47%)
We assign a fundamental rating of 4 out of 10 to NAVA. NAVA was compared to 53 industry peers in the Pharmaceuticals industry. NAVA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. NAVA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
NAVA had negative earnings in the past year.
NAVA had a positive operating cash flow in the past year.
In multiple years NAVA reported negative net income over the last 5 years.
In multiple years NAVA reported negative operating cash flow during the last 5 years.
1.2 Ratios
NAVA has a worse Return On Assets (-6.84%) than 67.92% of its industry peers.
The Return On Equity of NAVA (-15.33%) is worse than 69.81% of its industry peers.
NAVA has a Return On Invested Capital of 5.11%. This is comparable to the rest of the industry: NAVA outperforms 43.40% of its industry peers.
The Average Return On Invested Capital over the past 3 years for NAVA is below the industry average of 14.46%.
The 3 year average ROIC (10.14%) for NAVA is well above the current ROIC(5.11%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.84% | ||
| ROE | -15.33% | ||
| ROIC | 5.11% |
ROA(3y)1.27%
ROA(5y)-0.47%
ROE(3y)1.61%
ROE(5y)-1.5%
ROIC(3y)10.14%
ROIC(5y)N/A
1.3 Margins
The Operating Margin of NAVA (4.03%) is worse than 60.38% of its industry peers.
In the last couple of years the Operating Margin of NAVA has grown nicely.
NAVA's Gross Margin of 37.23% is on the low side compared to the rest of the industry. NAVA is outperformed by 75.47% of its industry peers.
In the last couple of years the Gross Margin of NAVA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.03% | ||
| PM (TTM) | N/A | ||
| GM | 37.23% |
OM growth 3Y13.14%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y5.2%
2. Health
2.1 Basic Checks
NAVA has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
NAVA has more shares outstanding than it did 1 year ago.
NAVA has more shares outstanding than it did 5 years ago.
NAVA has a better debt/assets ratio than last year.
2.2 Solvency
NAVA has an Altman-Z score of 2.51. This is not the best score and indicates that NAVA is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of NAVA (2.51) is comparable to the rest of the industry.
The Debt to FCF ratio of NAVA is 2.78, which is a good value as it means it would take NAVA, 2.78 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 2.78, NAVA is in the better half of the industry, outperforming 66.04% of the companies in the same industry.
NAVA has a Debt/Equity ratio of 0.33. This is a healthy value indicating a solid balance between debt and equity.
NAVA's Debt to Equity ratio of 0.33 is fine compared to the rest of the industry. NAVA outperforms 62.26% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.33 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 2.51 |
ROIC/WACC0.63
WACC8.09%
2.3 Liquidity
NAVA has a Current Ratio of 1.30. This is a normal value and indicates that NAVA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.30, NAVA is in line with its industry, outperforming 52.83% of the companies in the same industry.
A Quick Ratio of 0.71 indicates that NAVA may have some problems paying its short term obligations.
The Quick ratio of NAVA (0.71) is worse than 75.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.71 |
3. Growth
3.1 Past
The earnings per share for NAVA have decreased strongly by -236.79% in the last year.
NAVA shows a decrease in Revenue. In the last year, the revenue decreased by -3.67%.
Measured over the past years, NAVA shows a very strong growth in Revenue. The Revenue has been growing by 23.00% on average per year.
EPS 1Y (TTM)-236.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-107.47%
Revenue 1Y (TTM)-3.67%
Revenue growth 3Y24.05%
Revenue growth 5Y23%
Sales Q2Q%-12.17%
3.2 Future
NAVA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.39% yearly.
The Revenue is expected to grow by 12.79% on average over the next years. This is quite good.
EPS Next Y-111.04%
EPS Next 2Y2.39%
EPS Next 3Y18.86%
EPS Next 5Y31.39%
Revenue Next Year12.65%
Revenue Next 2Y18.54%
Revenue Next 3Y16.76%
Revenue Next 5Y12.79%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NAVA. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 15.77, the valuation of NAVA can be described as correct.
The rest of the industry has a similar Price/Forward Earnings ratio as NAVA.
The average S&P500 Price/Forward Earnings ratio is at 22.55. NAVA is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 15.77 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NAVA indicates a somewhat cheap valuation: NAVA is cheaper than 71.70% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, NAVA is valued a bit cheaper than the industry average as 79.25% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.83 | ||
| EV/EBITDA | 9.26 |
4.3 Compensation for Growth
NAVA's earnings are expected to grow with 18.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.39%
EPS Next 3Y18.86%
5. Dividend
5.1 Amount
NAVA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OSL:NAVA (10/31/2025, 7:00:00 PM)
21.4
-0.1 (-0.47%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners23.77%
Inst Owner ChangeN/A
Ins Owners12.68%
Ins Owner ChangeN/A
Market Cap513.17M
Revenue(TTM)523.56M
Net Income(TTM)-33200000
Analysts82.86
Price Target40.8 (90.65%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.23%
Min Revenue beat(2)-7.18%
Max Revenue beat(2)-5.28%
Revenue beat(4)0
Avg Revenue beat(4)-8.08%
Min Revenue beat(4)-17.93%
Max Revenue beat(4)-1.92%
Revenue beat(8)2
Avg Revenue beat(8)-3.62%
Revenue beat(12)4
Avg Revenue beat(12)-1.68%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)12.99%
EPS NQ rev (1m)-118.33%
EPS NQ rev (3m)-118.33%
EPS NY rev (1m)0%
EPS NY rev (3m)-119.31%
Revenue NQ rev (1m)0.14%
Revenue NQ rev (3m)0.14%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.42%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 15.77 | ||
| P/S | 0.98 | ||
| P/FCF | 12.83 | ||
| P/OCF | 11.83 | ||
| P/B | 2.37 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.26 |
EPS(TTM)-1.91
EYN/A
EPS(NY)1.36
Fwd EY6.34%
FCF(TTM)1.67
FCFY7.79%
OCF(TTM)1.81
OCFY8.46%
SpS21.83
BVpS9.03
TBVpS-1.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.84% | ||
| ROE | -15.33% | ||
| ROCE | 6.63% | ||
| ROIC | 5.11% | ||
| ROICexc | 5.98% | ||
| ROICexgc | 90.24% | ||
| OM | 4.03% | ||
| PM (TTM) | N/A | ||
| GM | 37.23% | ||
| FCFM | 7.64% |
ROA(3y)1.27%
ROA(5y)-0.47%
ROE(3y)1.61%
ROE(5y)-1.5%
ROIC(3y)10.14%
ROIC(5y)N/A
ROICexc(3y)12.6%
ROICexc(5y)N/A
ROICexgc(3y)98.8%
ROICexgc(5y)N/A
ROCE(3y)13.17%
ROCE(5y)N/A
ROICexgc growth 3Y90.11%
ROICexgc growth 5YN/A
ROICexc growth 3Y12.82%
ROICexc growth 5YN/A
OM growth 3Y13.14%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.68%
GM growth 5Y5.2%
F-Score4
Asset Turnover1.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.33 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.15 | ||
| Cap/Depr | 8.34% | ||
| Cap/Sales | 0.65% | ||
| Interest Coverage | 2.91 | ||
| Cash Conversion | 69.98% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.3 | ||
| Quick Ratio | 0.71 | ||
| Altman-Z | 2.51 |
F-Score4
WACC8.09%
ROIC/WACC0.63
Cap/Depr(3y)19.25%
Cap/Depr(5y)40.99%
Cap/Sales(3y)0.55%
Cap/Sales(5y)0.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-236.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-107.47%
EPS Next Y-111.04%
EPS Next 2Y2.39%
EPS Next 3Y18.86%
EPS Next 5Y31.39%
Revenue 1Y (TTM)-3.67%
Revenue growth 3Y24.05%
Revenue growth 5Y23%
Sales Q2Q%-12.17%
Revenue Next Year12.65%
Revenue Next 2Y18.54%
Revenue Next 3Y16.76%
Revenue Next 5Y12.79%
EBIT growth 1Y-55.6%
EBIT growth 3Y40.35%
EBIT growth 5YN/A
EBIT Next Year22.79%
EBIT Next 3Y32.76%
EBIT Next 5Y26.96%
FCF growth 1Y29.54%
FCF growth 3YN/A
FCF growth 5Y24.61%
OCF growth 1Y30.76%
OCF growth 3YN/A
OCF growth 5Y25.36%
NAVAMEDIC / NAVA.OL FAQ
Can you provide the ChartMill fundamental rating for NAVAMEDIC?
ChartMill assigns a fundamental rating of 4 / 10 to NAVA.OL.
What is the valuation status for NAVA stock?
ChartMill assigns a valuation rating of 4 / 10 to NAVAMEDIC (NAVA.OL). This can be considered as Fairly Valued.
What is the profitability of NAVA stock?
NAVAMEDIC (NAVA.OL) has a profitability rating of 3 / 10.